PDCD1 and metabolic dysfunction-associated steatotic liver disease: Last, we suggest that pharmacological HAS inhibition by 4-MU or 4-MUG and combination therapy with anti–PD-1 antibody could be a treatment option for patients with CRC liver metastasis with MASLD.